2. Signaling Pathways
  3. PROTAC
  4. PROTACs
  5. PROTACs Isoform
  6. PROTACs Inhibitor

PROTACs Inhibitor

PROTACs Inhibitors (10):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112588
    dBET6 1950634-92-0 99.92%
    dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for Cereblon and BET, with an IC50 of 14 nM, and has antitumor activity.
    dBET6
  • HY-130257
    CP5V 2509359-75-3 99.31%
    CP5V is a PROTAC connected by ligands for von Hippel-Lindau and CDK, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation.
    CP5V
  • HY-130256
    β-NF-JQ1 2380000-55-3 99.37%
    β-NF-JQ1 is a PROTAC that recruits Aryl Hydrocarbon Receptor E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity.
    β-NF-JQ1
  • HY-145125
    SJ995973 2882065-25-8 98.84%
    SJ995973 (PROTAC) is a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins.
    SJ995973
  • HY-155815
    MS9715
    MS9715 is a potent and seletive NSD3-targeting PROTAC. MS9715 is designed by BI-9321, which binds NSD3’s PWWP1 domain, with an E3 ligase VHL ligand. MS9715 has the potental for NSD3-dependent cancer treatment research.
    MS9715
  • HY-147330
    SJ1008030 2863634-96-0
    SJ1008030 (compound 8) is a JAK2 PROTAC which selectively degrades JAK2. SJ1008030 inhibits MHH–CALL-4 cell growth with an IC50 of 5.4 nM. SJ1008030 can be used for the research of leukemia.
    SJ1008030
  • HY-145947
    PROTAC BRD9 Degrader-5 2704616-86-2
    PROTAC BRD9 Degrader-5 is a PROTAC for targeted degradation of BRD9.
    PROTAC BRD9 Degrader-5
  • HY-144323
    YF135 2913177-53-2
    YF135 is an efficient and reversible-covalent KRASG12C PROTAC. YF135 is designed and synthesized by tethering KRAS G12C inhibitor 48 (compound 6d) as the ligand, and basing on the scaffold of MRTX849 linkage VHL ligand. YF135 significantly induces the degradation of KRASG12C in a reversible manner and decreases phospho-ERK level through the E3 ligase VHL mediated proteasome pathway.
    YF135
  • HY-168229
    PROTAC SMARCA2 degrader-27 2410314-57-5
    PROTAC SMARCA2 degrader-27 (compound 4) is a PROTAC SMARCA2 degrader. PROTAC SMARCA2 degrader-27 has the potential to be used in cancer research (blue: SMARCA2 ligand, (HY-168232); black: linker, (HY-168231); pink: VHL ligand, (HY-168230)).
    PROTAC SMARCA2 degrader-27
  • HY-155150
    JH-XII-03-02 2415900-86-4 99.41%
    JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD) research.
    JH-XII-03-02